Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors

키워드

참고문헌 (91)

1. Mach F, "2019 ESC", EAS Guidelines for the management of dyslipidaemias : lipid modification to reduce cardiovascular risk, 2020, pp.41, 111~188
2. Ference BA, "Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel", Eur Heart J, 38, pp.2459~2472 (2017)
3. Grundy SM, "2018 AHA", ACC, AAPA, pp.ABC, ACPM[DOI]
4. Nissen SE, "Bempedoic acid and cardiovascular outcomes in statin-intolerant patients", N Engl J Med, 388, pp.1353~1364 (2023)
5. Tokgözoğlu L, "The dawn of a new era of targeted lipid-lowering therapies", Eur Heart J, 43, pp.3198~3208 (2022)
6. Laufs U, "Clinical review on triglycerides", Eur Heart J, 41, pp.99~109 (2020)
7. Ginsberg HN, "Triglyceride-rich lipoproteins and their remnants : metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society", Eur Heart J, 42, pp.4791~4806 (2021)
8. Ference BA, "Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease", JAMA, 321, pp.364~373 (2019)
9. Marston NA, "Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes : a systematic review and meta-regression analysis of randomized controlled trials", Circulation, 140, pp.1308~1317 (2019)
10. Bhatt DL, "Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia", N Engl J Med, 380, pp.11~22 (2019)
11. Grundy SM, "2018 AHA", ACC, AAPA, pp.ABC, ACPM[DOI]
12. Tall AR, "Addressing dyslipidemic risk beyond LDL-cholesterol", J Clin Invest, 132, pp.e148559~ (2022)
13. Conklin D, "Identification of a mammalian angiopoietin-related protein expressed specifically in liver", Genomics, 62, pp.477~482 (1999)
14. Shimizugawa T, "ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase", J Biol Chem, 277, pp.33742~33748 (2002)
15. Shimamura M, "Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase", Arterioscler Thromb Vasc Biol, 27, pp.366~372 (2007)
16. Adam RC, "Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance", J Lipid Res, 61, pp.1271~1286 (2020)
17. Wu L, "LDL-cholesterol reduction by ANGPTL3 inhibition in mice is dependent on endothelial lipase", Circ Res, 127, pp.1112~1114 (2020)
18. Thomas DG, "Lipid and metabolic syndrome traits in coronary artery disease : a Mendelian randomization study", J Lipid Res, 62, pp.100044~ (2021)
19. Ruppert PM, "Fasting induces ANGPTL4 and reduces LPL activity in human adipose tissue", Mol Metab, 40, pp.101033~ (2020)
20. Chen YQ, "Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids", J Lipid Res, 61, pp.1203~1220 (2020)
21. Athyros VG, "Drugs that mimic the effect of gene mutations for the prevention or the treatment of atherosclerotic disease : from PCSK9 inhibition to ANGPTL3 inactivation", Curr Pharm Des, 24, pp.3638~3646 (2018)
22. Dewey FE, "Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease", N Engl J Med, 377, pp.211~221 (2017)
23. Dewey FE, "Inactivating variants in ANGPTL4 and risk of coronary artery disease", N Engl J Med, 374, pp.1123~1133 (2016)
24. Desai U, "Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice", Proc Natl Acad Sci U S A, 104, pp.11766~11771 (2007)
25. Gusarova V, "ANGPTL8 blockade with a monoclonal antibody promotes triglyceride clearance, energy expenditure, and weight loss in mice", Endocrinology, 158, pp.1252~1259 (2017)
26. Chen PY, "Angiopoietin-like protein 3(ANGPTL3)modulates lipoprotein metabolism and dyslipidemia", Int J Mol Sci, 22, pp.7310~ (2021)
27. Murphy AJ, "Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice", Proc Natl Acad Sci U S A, 111, pp.5153~5158 (2014)
28. Gusarova V, "ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys", J Lipid Res, 56, pp.1308~1317 (2015)
29. Ahmad Z, "Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia", Circulation, 140, pp.470~486 (2019)
30. Harada-Shiba M, "A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects", Atherosclerosis, 314, pp.33~40 (2020)
31. Gaudet D, "ANGPTL3 inhibition in homozygous familial hypercholesterolemia", N Engl J Med, 377, pp.296~297 (2017)
32. Rosenson RS, "Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations : a phase 2 randomized trial", Nat Med, 29, pp.729~737 (2023)
33. Raal FJ, "Evinacumab for homozygous familial hypercholesterolemia", N Engl J Med, 383, pp.711~720 (2020)
34. Rosenson RS, "Evinacumab in patients with refractory hypercholesterolemia", N Engl J Med, 383, pp.2307~2319 (2020)
35. Banerjee P, "Functional analysis of LDLR(low-density lipoprotein receptor)variants in patient lymphocytes to assess the effect of evinacumab in homozygous familial hypercholesterolemia patients with a spectrum of LDLR activity", Arterioscler Thromb Vasc Biol, 39, pp.2248~2260 (2019)
36. Kuehn BM, "Evinacumab approval adds a new option for homozygous familial hypercholesterolemia with a hefty price tag", Circulation, 143, pp.2494~2496 (2021)
37. Reeskamp LF, "ANGPTL3 inhibition with evinacumab results in faster clearance of IDL and LDL apoB in patients with homozygous familial hypercholesterolemia-brief report", Arterioscler Thromb Vasc Biol, 41, pp.1753~1759 (2021)
38. Reeskamp LF, "Marked plaque regression in homozygous familial hypercholesterolemia", Atherosclerosis, 327, pp.13~17 (2021)
39. Jin M, "Efficacy and safety of evinacumab for the treatment of hypercholesterolemia : a meta-analysis", J Cardiovasc Pharmacol, 78, pp.394~402 (2021)
40. Ruscica M, "Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors : New therapeutic approaches for the treatment of atherogenic dyslipidemia", Pharmacol Res, 153, pp.104653~ (2020)
41. Brandt TA, "ISIS-ANGPTL3RX, an antisense inhibitor to angiopoietin-like 3, reduces plasma lipid levels in mouse models and in healthy human volunteers", Atherosclerosis, 241, pp.e30~ (2015)
42. Graham MJ, "Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides", N Engl J Med, 377, pp.222~232 (2017)
43. Gaudet D, "Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia", Eur Heart J, 41, pp.3936~3945 (2020)
44. Bergmark BA, "Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol : TRANSLATE-TIMI 70", Circulation, 145, pp.1377~1386 (2022)
45. "Pfizer and Ionis Announce Discontinuation of Vupanorsen Clinical Development Program" (2022)[URL]
46. Watts GF, "RNA interference targeting hepatic angiopoietin-like protein 3 results in prolonged reductions in plasma triglycerides and LDL-C in human subjects", Circulation, 140, pp.E987~988 (2019)
47. Watts GF, "RNAi inhibition of angiopoietin-like protein 3(ANGPTL3)with ARO-ANG3 mimics the lipid and lipoprotein profile of familial combined hypolipidemia", Eur Heart J, 41(Suppl 2), pp.ehaa946.3331~ (2020)
48. Watts GF, "Abstract 15751: pharmacodynamic effect of ARO-ANG3, an investigational RNA interference targeting hepatic angiopoietin-like protein 3, in patients with hypercholesterolemia", Circulation, 142(Suppl 3), pp.A15751~ (2020)
49. "ARO-ANG3, an Investigational RNAi Therapeutic, Decreases Serum LDL-Cholesterol, Apolipoprotein B, and Angiopoietin-like Protein 3 in Patients with Homozygous Familial Hypercholesterolaemia" (2023)[URL]
50. "Medicines in Development" (2023)[URL]
51. "Kyttaro Announces Worldwide Exclusive Licensing Agreement with Lilly for Antibody Therapeutic Program" (2023)[URL]
52. Balasubramaniam D, "An anti-ANGPTL3", 8 antibody decreases circulating triglycerides by binding to a LPL-inhibitory leucine zipper-like motif, 2022, pp.63, 100198~
53. Fowler A, "A VLP-based vaccine targeting ANGPTL3 lowers plasma triglycerides in mice", Vaccine, 39, pp.5780~5786 (2021)
54. Fukami H, "Vaccine targeting ANGPTL3 ameliorates dyslipidemia and associated diseases in mouse models of obese dyslipidemia and familial hypercholesterolemia", Cell Rep Med, 2, pp.100446~ (2021)
55. Chadwick AC, "Reduced blood lipid levels with in vivo CRISPR-Cas9 base editing of ANGPTL3", Circulation, 137, pp.975~977 (2018)
56. Qiu M, "Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3", Proc Natl Acad Sci U S A, 118, pp.e2020401118~ (2021)
57. Li WW, "Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia", J Clin Invest, 96, pp.2601~2605 (1995)
58. Caron S, "Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia", Arterioscler Thromb Vasc Biol, 31, pp.513~519 (2011)
59. Forcheron F, "Mechanisms of the triglyceride-and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients", Diabetes, 51, pp.3486~3491 (2002)
60. Gibson WT, "Beneficial metabolic phenotypes caused by loss-of-function APOC3 mutations", Clin Genet, 87, pp.31~32 (2015)
61. Jørgensen AB, "Loss-of-function mutations in APOC3 and risk of ischemic vascular disease", N Engl J Med, 371, pp.32~41 (2014)
62. Natarajan P, "Association of APOC3 loss-of-function mutations with plasma lipids and subclinical atherosclerosis : the multi-ethnic bioimage study", J Am Coll Cardiol, 66, pp.2053~2055 (2015)
63. Crosby J, "Loss-of-function mutations in APOC3, triglycerides, and coronary disease", N Engl J Med, 371, pp.22~31 (2014)
64. Wulff AB, "APOC3 loss-of-function mutations, remnant cholesterol, low-density lipoprotein cholesterol, and cardiovascular risk : mediation-and meta-analyses of 137 895 individuals", Arterioscler Thromb Vasc Biol, 38, pp.660~668 (2018)
65. Gordts PL, "ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors", J Clin Invest, 126, pp.2855~2866 (2016)
66. Ramms B, "ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance", J Lipid Res, 60, pp.1379~1395 (2019)
67. Gugliucci A, "Triglyceride-rich lipoprotein metabolism : key regulators of their flux", J Clin Med, 12, pp.4399~ (2023)
68. Sundaram M, "Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions", J Lipid Res, 51, pp.150~161 (2010)
69. Milonas D, "Experimental therapies targeting apolipoprotein C-III for the treatment of hyperlipidemia-spotlight on volanesorsen", Expert Opin Investig Drugs, 28, pp.389~394 (2019)
70. Paik J, "Volanesorsen : first global approval", Drugs, 79, pp.1349~1354 (2019)
71. "FDA Rejects Volanesorsen (Waylivra) for Rare Triglyceride Disorder" (2019)[URL]
72. Graham MJ, "Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans", Circ Res, 112, pp.1479~1490 (2013)
73. Gaudet D, "Targeting APOC3 in the familial chylomicronemia syndrome", N Engl J Med, 371, pp.2200~2206 (2014)
74. Gaudet D, "Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia", N Engl J Med, 373, pp.438~447 (2015)
75. Digenio A, "Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes", Diabetes Care, 39, pp.1408~1415 (2016)
76. Witztum JL, "Volanesorsen and triglyceride levels in familial chylomicronemia syndrome", N Engl J Med, 381, pp.531~542 (2019)
77. Gouni-Berthold I, "Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia(COMPASS) : a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial", Lancet Diabetes Endocrinol, 9, pp.264~275 (2021)
78. Post N, "Metabolism and disposition of volanesorsen, a 2′-O-(2 methoxyethyl)antisense oligonucleotide, across species", Drug Metab Dispos, 47, pp.1164~1173 (2019)
79. Witztum JL, "Volanesorsen and triglyceride levels in familial chylomicronemia syndrome : long-term efficacy and safety data from patients in an open-label extension trial", J Clin Lipidol, 17, pp.342~355 (2023)
80. Davidson M, "The burden of familial chylomicronemia syndrome : Results from the global IN-FOCUS study", J Clin Lipidol, 12, pp.898~907 (2018)
81. Arca M, "The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome : the results of the ReFOCUS study", Expert Rev Cardiovasc Ther, 16, pp.537~546 (2018)
82. Jones A, "Long-term effects of volanesorsen on triglycerides and pancreatitis in patients with familial chylomicronaemia syndrome(FCS)in the UK Early Access to Medicines Scheme(EAMS)", Atherosclerosis, 375, pp.67~74 (2023)
83. Lightbourne M, "Volanesorsen, an antisense oligonucleotide to apolipoprotein C-III, increases lipoprotein lipase activity and lowers triglycerides in partial lipodystrophy", J Clin Lipidol, 16, pp.850~862 (2022)
84. Oral EA, "Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy : Results of the BROADEN study : Volanesorsen in FPLD; The BROADEN Study", J Clin Lipidol, 16, pp.833~849 (2022)
85. Prohaska TA, "APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia", J Clin Lipidol, 17, pp.406~411 (2023)
86. Alexander VJ, "N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels", Eur Heart J, 40, pp.2785~2796 (2019)
87. Tardif JC, "Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk", Eur Heart J, 43, pp.1401~1412 (2022)
88. Schwabe C, "RNA interference targeting apolipoprotein C-III with ARO-APOC3 in healthy volunteers mimics lipid and lipoprotein findings seen in subjects with inherited apolipoprotein C-III deficiency", Eur Heart J, 41, pp.ehaa946.3330~ (2020)
89. Clifton P, "Abstract 12594 : pharmacodynamic effect of ARO-APOC3, an investigational hepatocyte-targeted RNA interference therapeutic targeting apolipoprotein C3, in patients with hypertriglyceridemia and multifactorial chylomicronemia", Circulation, 142(Suppl 3), pp.A12594~ (2020)
90. Clifton P, "Abstract 10357 : ARO-APOC3, an investigational RNAi therapeutic, shows similar efficacy and safety in genetically confirmed FCS and non-FCS participants with severe hypertriglyceridemia", Circulation, 144(Suppl 1), pp.A10357~ (2021)
91. Khetarpal SA, "A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels", Nat Med, 23, pp.1086~1094 (2017)

관련 논문AI추천